<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03398655</url>
  </required_header>
  <id_info>
    <org_study_id>VB-111-701/GOG-3018</org_study_id>
    <nct_id>NCT03398655</nct_id>
  </id_info>
  <brief_title>A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)</brief_title>
  <acronym>OVAL</acronym>
  <official_title>A Randomized, Controlled, Double-Arm, Open-Label, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Monotherapy for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vascular Biogenics Ltd. operating as VBL Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GOG Foundation, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vascular Biogenics Ltd. operating as VBL Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase 3, randomized, multicenter study is to compare VB-111 plus
      paclitaxel to paclitaxel in adult patients with Recurrent Platinum-Resistant Ovarian Cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2017</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of study entry until the date of death from any cause (up to 5 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Combined CA-125 and RECIST 1.1 response (GCIG)</measure>
    <time_frame>From date of study entry until the date of death from any cause (up to 5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CA-125 Response (GCIG)</measure>
    <time_frame>From date of study entry until the date of death from any cause (up to 5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) by RECIST 1.1</measure>
    <time_frame>From date of study entry until the date of death from any cause (up to 5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) by RECIST 1.1</measure>
    <time_frame>From date of study entry until the date of death from any cause (up to 5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) by irRECIST</measure>
    <time_frame>From date of study entry until the date of death from any cause (up to 5 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Recurrent Platinum Resistant Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VB-111 + Paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VB-111 + Paclitaxel</intervention_name>
    <description>VB-111 will be administered intravenously at a dose of 1x10e13 VPs every 2 months Paclitaxel will be administered intravenously at a dose of 80mg/m2 every week</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel will be administered intravenously at a dose of 80mg/m2 every week</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female patients ≥18 years of age

          2. Histologically confirmed epithelial ovarian cancer (mucinous adenocarcinoma, clear
             cell carcinomas and grade 1 serous tumors are excluded) and documented disease.

          3. Patients must have platinum-resistant disease

          4. Patients must have disease that is measurable according to RECIST 1.1 and require
             chemotherapy treatment.

          5. ECOG PS 0-2.

          6. Adequate hematological functions:

               -  ANC ≥ 1000/mm3

               -  PLT ≥ 100,000/mm3

               -  PT and PTT (seconds) &lt; 1.2 X ULN. Patients who are anticoagulated do not need to
                  meet criteria for PT and PTT.

        Exclusion Criteria:

          1. Non-epithelial tumors (Carcino-sarcomas are excluded)

          2. Ovarian tumors with low malignant potential (i.e. borderline tumors) and mucinous
             tumors.

          3. History of other clinically active malignancy within 5 years of enrollment, except for
             tumors with a negligible risk for metastasis or death, such as adequately controlled
             basal-cell carcinoma, adequately controlled, non-metastatic squamous-cell carcinoma of
             the skin, or carcinoma in situ of the cervix or breast.

          4. Previous ovarian cancer treatment with &gt;3 anticancer regimens.

          5. Any prior radiotherapy to the pelvis or abdomen.

          6. Inadequate liver function, defined as:

               -  Serum (total) bilirubin &gt; ULN (Exception: documented Gilbert's disease patients
                  can be enrolled)

               -  Alkaline phosphatase, AST/SGOT or ALT/SGPT ≥2.5 x ULN (or ≥ 5 x ULN in the
                  presence of liver metastases).

          7. Inadequate renal function, defined as:

               -  Serum creatinine &gt; ULN OR

               -  Calculated creatinine clearance &lt; 50ml/min (by Cockroft &amp; Gault formula

        and renal function 7. New York Heart Association (NYHA) Grade II or greater congestive
        heart failure 8. History of myocardial infarction or unstable angina within 6 months prior
        to day of randomization.

        9. History of stroke or transient ischemic attack within 6 months prior to day of
        randomization.

        10. Patient with proliferative and/or vascular retinopathy 11. Known brain metastases 12.
        History of hemoptysis or active GI bleeding within 6 month prior to day of randomization
        13. Evidence of bleeding diathesis or significant coagulopathy (in the absence of
        therapeutic anticoagulation).

        14. History of abdominal fistula or gastrointestinal perforation. 15. Current signs and
        symptoms of bowel obstruction 16. Uncontrolled active infection
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard Penson, MD</last_name>
    </contact>
    <investigator>
      <last_name>Richard Penson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tali Lifshits-Gritzman</last_name>
      <phone>972-4-7771796</phone>
      <email>gyn_onco@rambam.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Amnon Amit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shaare Tzedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dalia Sherizen</last_name>
      <phone>972-2-6555424</phone>
      <email>daliash@szmc.org.il</email>
    </contact>
    <investigator>
      <last_name>Ora Rosengarten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Almog Chotiner</last_name>
      <phone>03-5307033</phone>
      <email>Almog.Chotiner@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Ronnie Shapira-Frommer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.vblrx.com/</url>
    <description>VBL Therapeutics Company Website</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2018</study_first_submitted>
  <study_first_submitted_qc>January 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2018</study_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recurrent Ovarian cancer</keyword>
  <keyword>Platinum resistant ovarian cancer</keyword>
  <keyword>Ovarian cancer</keyword>
  <keyword>Ovarian carcinoma</keyword>
  <keyword>Epithelial ovarian cancer</keyword>
  <keyword>paclitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

